G2GBIO, "Remarkable outcomes in non-clinical study for their Semaglutide microspheres"

(Monthly sustained-release diabetes/obesity treatment)

- Confirmed "28-day maintenance of drug concentration in the body" along with a "significant decrease in injection site reactions"

- Planned to be presented at the upcoming American Diabetes Association (ADA) conference in June

G2GBIO, a biopharmaceutical company, has announced the successful outcomes of a non-clinical study involving Semaglutide microspheres (GB-7001). The study demonstrated consistent drug concentration in the body for approximately one month, along with a notable reduction in inflammation at the injection site.

On the 11th, G2GBIO disclosed its intentions to present these findings at the upcoming American Diabetes Association (ADA) conference, scheduled to take place in San Diego, United States, in June. Additionally, the company announced that it is conducting joint material evaluation with global pharmaceutical company for technology export.

According to G2GBIO, they administered high Semaglutide-loaded microspheres via subcutaneous injection to rats and mini-pigs and observed the drug concentration in the bloodstream was maintained above a certain threshold for 28 days without initial burst. Subsequently, the drug continued to gradually released over time, and it was found to persist in the body for nearly two months. 

It is widely recognized in the industry that the ability to produce microspheres with high drug loading while suppressing initial release is a critical factor determining the competitiveness of GLP-1 analogue-based diabetes and obesity treatments. In comparison to Bydureon, a commercialized GLP-1 analogue with a drug loading of 5%, G2GBIO's GB-7001 is evaluated to possess an unparalleled competitive advantage.

Furthermore, G2GBIO's Semaglutide microspheres demonstrated a remarkable reduction in injection site reactions compared to conventional microspheres. G2GBIO stated that this improvement in injection site reactions was observed not only with placebo microspheres but also in microspheres containing Tirzepatide, which belong to the same GLP-1 analogues used for diabetes treatment. G2GBIO explained that this approach can be applied to various microspheres with different GLP-1 analogue drugs. Experts highlight that minimizing inflammation at the injection site is a crucial factor for the successful commercialization of long-acting diabetes treatment drugs.

G2GBIO plans to present these study results at the American Diabetes Association (ADA) conference, scheduled to take place in San Diego, California, United States from June 23rd to 26th.

CEO of G2GBIO, Heeyong Lee, stated, "We will develop formulations that allow for monthly or even three-monthly subcutaneous injectables, replacing the existing weekly injectables." He also mentioned that “This development aims to significantly improve patient convenience in medication administration and enhance medication adherence, ultimately maximizing the therapeutic effectiveness”.

Originally developed as a diabetes treatment, Semaglutide gained attention as a "game-changer in obesity treatment" due to its significant weight loss effects. Last year, it has experienced remarkable growth, with global sales exceeding 10 billion USD, becoming a prominent medication in the market.